Deuterium

Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, June 27, 2023
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Learning, DMT, Inc., IV, Power purchase agreement, Calendar, US, Sales management, MDD, DSM-IV codes, Patent, Deuterium, Ecosystem, NYSE, Safety, NEO, Pharmaceutical industry

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported audited financial results for its fiscal year ended March 31, 2023, and recent business highlights.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported audited financial results for its fiscal year ended March 31, 2023, and recent business highlights.
  • CYB003 was well-tolerated at the doses evaluated (single oral doses of 1mg, 3mg, 8mg, and 10mg) with no serious adverse events reported.
  • Depending on market conditions and operating needs, this may provide Cybin with access to additional cash for growth opportunities and working capital.
  • As of June 27, 2023, under the previously announced Purchase Agreement, Cybin has the option to sell up to an additional US$29.5 (C$39.8) million of common shares at its discretion.

Mitsubishi Corporation Invests in Kyoto Fusioneering, a spin-off from Kyoto University

Retrieved on: 
Wednesday, May 17, 2023
Carbon, Deuterium, University, MC, Electricity, KF, Light, Research, Government, Tritium, Seawater, Kyoto University, Helium, CO2, Lithium, Renewable energy

Its establishment in 2019 was based on decades of fusion research and development by Kyoto University.

Key Points: 
  • Its establishment in 2019 was based on decades of fusion research and development by Kyoto University.
  • KF specializes in key components and integrated systems that are required in order to build fusion reactors and fusion power plants.
  • KF's strategic aim is to build a fusion energy supply chain by leveraging Japan's leading manufacturing capabilities.
  • (Based on the provisional translation of "Fusion Energy Innovation Strategy" adopted by Japan's Integrated Innovation Strategy Promotion Council on April 14, 2023)

Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, DMT, Deuterium, Human, Inc., IV, NYSE, Medicare Part D, NEO, Pharmaceutical industry, Part

With the achievement of this milestone, Cybin intends to initiate Part C of the study, the first-in-human dosing of its proprietary DMT molecule CYB004.

Key Points: 
  • With the achievement of this milestone, Cybin intends to initiate Part C of the study, the first-in-human dosing of its proprietary DMT molecule CYB004.
  • The Company expects to report topline data from the completed Phase 1 study in the third quarter of calendar year 2023.
  • These data demonstrated a dose-proportional increase in exposure and dose-related increase in behavioral measures of subjective psychedelic experience with IV DMT.
  • Additionally, IV DMT was well-tolerated with no safety issues and no serious adverse events within the dose range evaluated.

Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, April 5, 2023
USAN, Attack, International, Association of International Accountants, Bank statement, Deuterium, Hereditary angioedema, Record, American Academy, G&A, American Medical Association, HAE, Administration, Annual general meeting, AMA, AAAAI, INN, Research and development, WHO, Research, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Book, Food, International Accounting Standards Board, Vaccine, Cryptocurrency, Pharmaceutical industry, Video game

Based on the Company’s current assessment of the ex-U.S. regulatory status and enrollment rates, Pharvaris anticipates announcing top-line data in the second half of 2023.

Key Points: 
  • Based on the Company’s current assessment of the ex-U.S. regulatory status and enrollment rates, Pharvaris anticipates announcing top-line data in the second half of 2023.
  • R&D expenses were €15.7 million for the fourth quarter and €57.4 million for the full year of 2022, compared to €10.7 million for the fourth quarter and €35.8 million for the full year of 2021.
  • Loss for the fourth quarter was €39.2 million, resulting in basic and diluted loss per share of €1.16.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Alternative Medicine, Health, Mental Health, DMT, Generalized anxiety disorder, PD, Depression, Deuterium, NYSE, Research, Absorption, Massachusetts General Hospital, Patient, NEO, MGH, Plasma, Harvard Medical School, Acceleration, Inc., Psychedelic drug, Calendar, Psychiatry, IV, Dean (education), PK, Hospital, Pharmaceutical industry, Part

Interim findings from the Company's ongoing Phase 1/2a clinical trial evaluating CYB003 demonstrated positive observations, including a rapid and short-acting psychedelic response in participants.

Key Points: 
  • Interim findings from the Company's ongoing Phase 1/2a clinical trial evaluating CYB003 demonstrated positive observations, including a rapid and short-acting psychedelic response in participants.
  • As of the date of this press release, Phase 1 dosing has been completed and the Phase 2a portion of the trial has commenced.
  • Cybin expects to report top-line results from the completed Phase 1/2a clinical trial in late third quarter of calendar year 2023.
  • The Company will provide further information on the interim readout from its ongoing CYB003 Phase 1/2a trial and additional updates on its CYB004 program.

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Retrieved on: 
Thursday, January 19, 2023
Learning, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Deuterium, Food, Patient, Investigational New Drug, NHL, Clinical trial, Society, Pharmaceutical industry, Salinicola salarius

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that Aundrietta Duncan, Ph.D., director of non-clinical development, will present SP-3164 preclinical data and discuss program progress at the inaugural Molecular Glue Drug Development Summit being held on January 24-26, 2023 in Boston.

Key Points: 
  • Dr. Duncan’s presentation, titled “Development of the Cereblon-Binding Molecular Glue, SP-3164,” will take place during the afternoon session on January 26.
  • “We are delighted two of our senior drug developers will have a prominent presence at the inaugural Molecular Glue Drug Development Summit.
  • I believe the fact there is a new event focused exclusively on advancing molecular glue degraders is testament to their potential to pursue drug targets previously considered undruggable.
  • We are looking forward to discussing SP-3164 and learning about other protein degrader programs,” commented David Arthur, president and chief executive officer of Salarius.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Janus, Disease, Sun Pharma, BSE, NSE, Autoimmune disease, R, CNCE, JAK1, CVR, Depression, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Safety, Deuterium, FDA, Hair loss, NDA, Woman, Immune system, Scalp, Food, Patient, CVR Partners, JAK2, Sale, Acquisition, Multimedia, Janus kinase, Reuters, Alopecia areata, Life, Investment, Concert, Hair, Wardwell, Security (finance), Pharmaceutical industry, Ophthalmology

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.

Key Points: 
  • Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime1,2,3.
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma.
  • “There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.

General Atomics Contributes to First Recorded Fusion Ignition at Lawrence Livermore National Laboratory

Retrieved on: 
Monday, December 19, 2022
Ignition, United States national laboratories, Deuterium, General Atomics, DOE, NNSA, Burn, Research, Record, Organization, National Nuclear Security Administration, Laboratory, Lawrence Livermore National Laboratory, Fusion rocket, MJ, LLNL, Private sector, Sandia National Laboratories, Field line, ICF, Plasma, The Energy Group, Inertial confinement fusion, University, National Ignition Facility, MFE, Senior, WEC Energy Group, Los Alamos National Laboratory, Lithium, 3D printing, Science

San Diego, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Precision components fabricated and processed by General Atomics (GA) helped to facilitate a record-breaking Inertial Confinement Fusion (ICF) experiment at the National Ignition Facility (NIF) at Lawrence Livermore National Laboratory (LLNL).

Key Points: 
  • San Diego, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Precision components fabricated and processed by General Atomics (GA) helped to facilitate a record-breaking Inertial Confinement Fusion (ICF) experiment at the National Ignition Facility (NIF) at Lawrence Livermore National Laboratory (LLNL).
  • During the experiment, conducted on December 5, 2022, a total of 2.05 megajoules (MJ) of energy were delivered to the target assembly, resulting in 3.15 MJ of fusion energy output.
  • The record-breaking result at NIF demonstrates the importance of public investment in fusion science and robust collaboration with the private sector.
  • IFE would differ from another approach to achieving fusion energy, known as Magnetic Fusion Energy (MFE), which uses magnetic fields to confine the plasma.